Why the study?
Does captopril improve hemodynamic parameters in dogs with surgically created mitral regurgitation?
Does captopril improve hemodynamic parameters in dogs with surgically created mitral regurgitation?
Captopril provides sustained hemodynamic improvement in a canine model of mitral regurgitation, suggesting a potential role in delaying congestive heart failure.
Supports sustained hemodynamic effects of captopril in canine mitral regurgitation; hypothesis-generating and should not yet change practice.
Mitral regurgitation was created surgically in 10 dogs. After measurement of baseline hemodynamic parameters on day 2, treatment with captopril (2 mg/kg orally 3 times daily) was begun in five dogs. Five control dogs received no therapy during the study. The hemodynamic parameters were measured again at weeks 6 and 22. In the treated dogs, the forward ejection fraction (FEF) increased slightly and the total peripheral resistance index (TPRI) decreased. In the controls, the FEF decreased and the TPRI increased. Changes in FEF and TPRI were significantly different between the two groups. The change in FEF correlated significantly with the change in TPRI in both groups. Although the most dramatic changes were observed at week 6, the differences persisted throughout the study. Captopril administration resulted in sustained hemodynamic improvement and may, therefore, delay the onset of congestive heart failure in dogs with mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
BLACKFORD et al. (1990) studied this question.